Literature DB >> 16477001

Activated Src abrogates the Myc requirement for the G0/G1 transition but not for the G1/S transition.

Tulsiram Prathapam1, Sarah Tegen, Thordur Oskarsson, Andreas Trumpp, G Steven Martin.   

Abstract

The transcription factor Myc plays a central role in the control of cellular proliferation. Myc expression is induced by growth factors in a pathway mediated by cellular Src (c-Src), but it is not clear whether Myc induction or activity is required for malignant transformation by activated Src. We introduced v-Src into a c-myc(-/-) derivative of Rat-1 fibroblasts and into 3T9 mouse fibroblasts harboring a conditionally excisable c-myc allele. Expression of activated viral Src in Myc-deficient cells led to loss of actin stress fibers and surface fibronectin, indicating that Myc is dispensable for v-Src-induced morphological transformation. However, v-Src failed to rescue the proliferative defect resulting from the loss of Myc. In Myc-deficient cells, despite its inability to overcome this proliferation block, v-Src was able to regulate the expression of certain Myc transcriptional targets and induce the expression of active cyclin D/Cdk4 and Cdk6 complexes; it also induced the phosphorylation of Rb, albeit at reduced levels. In contrast, however, in the absence of Myc, the level of Cdk2 kinase activity was drastically reduced. This reduction in Cdk2 activity was associated with a decrease in the expression of Cdk7, Cdc25A, and cyclin A. Coexpression of Cdk2 plus cyclin E and/or cyclin A rescued the G1/S block and allowed the cells to enter mitosis. These results indicate that in the absence of Myc, v-Src can activate early G1 cell cycle regulators but fails to activate regulators of the late G1/S transition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16477001      PMCID: PMC1413844          DOI: 10.1073/pnas.0511186103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis.

Authors:  T Bowman; M A Broome; D Sinibaldi; W Wharton; W J Pledger; J M Sedivy; R Irby; T Yeatman; S A Courtneidge; R Jove
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

2.  Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases.

Authors:  A K Indra; X Warot; J Brocard; J M Bornert; J H Xiao; P Chambon; D Metzger
Journal:  Nucleic Acids Res       Date:  1999-11-15       Impact factor: 16.971

3.  Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.

Authors:  W Yang; J Shen; M Wu; M Arsura; M FitzGerald; Z Suldan; D W Kim; C S Hofmann; S Pianetti; R Romieu-Mourez; L P Freedman; G E Sonenshein
Journal:  Oncogene       Date:  2001-03-29       Impact factor: 9.867

4.  The mechanism of cell cycle regulation by v-Src.

Authors:  D Riley; N O Carragher; M C Frame; J A Wyke
Journal:  Oncogene       Date:  2001-09-20       Impact factor: 9.867

Review 5.  Function of the c-Myc oncoprotein in chromatin remodeling and transcription.

Authors:  B Amati; S R Frank; D Donjerkovic; S Taubert
Journal:  Biochim Biophys Acta       Date:  2001-03-21

6.  Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression.

Authors:  R C O'Hagan; M Ohh; G David; I M de Alboran; F W Alt; W G Kaelin; R A DePinho
Journal:  Genes Dev       Date:  2000-09-01       Impact factor: 11.361

7.  Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling.

Authors:  D Sinibaldi; W Wharton; J Turkson; T Bowman; W J Pledger; R Jove
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

8.  Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation.

Authors:  S R Frank; M Schroeder; P Fernandez; S Taubert; B Amati
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

9.  SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling.

Authors:  R A Blake; M A Broome; X Liu; J Wu; M Gishizky; L Sun; S A Courtneidge
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

10.  The ornithine decarboxylase gene is a transcriptional target of c-Myc.

Authors:  C Bello-Fernandez; G Packham; J L Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

View more
  19 in total

Review 1.  SRC: a century of science brought to the clinic.

Authors:  Alexey Aleshin; Richard S Finn
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

2.  p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.

Authors:  Tulsiram Prathapam; Alexey Aleshin; Yinghui Guan; Joe W Gray; G Steven Martin
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

3.  c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.

Authors:  H Wang; S Mannava; V Grachtchouk; D Zhuang; M S Soengas; A V Gudkov; E V Prochownik; M A Nikiforov
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

4.  Stabilizers of the Max homodimer identified in virtual ligand screening inhibit Myc function.

Authors:  Hao Jiang; Kristen E Bower; Albert E Beuscher; Bin Zhou; Andrey A Bobkov; Arthur J Olson; Peter K Vogt
Journal:  Mol Pharmacol       Date:  2009-06-04       Impact factor: 4.436

5.  Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene.

Authors:  Thordur Oskarsson; Marieke Alida Gertruda Essers; Nicole Dubois; Sandra Offner; Christelle Dubey; Catherine Roger; Daniel Metzger; Pierre Chambon; Edith Hummler; Peter Beard; Andreas Trumpp
Journal:  Genes Dev       Date:  2006-08-01       Impact factor: 11.361

6.  Human Breast Cancer Stem Cells Have Significantly Higher Rate of Clathrin-Independent and Caveolin-Independent Endocytosis than the Differentiated Breast Cancer Cells.

Authors:  Kanagaraj Palaniyandi; Barbara A Pockaj; Sandra J Gendler; Xiu-Bao Chang
Journal:  J Cancer Sci Ther       Date:  2012-07-26

7.  Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

Authors:  Y-M Chang; L Bai; S Liu; J C Yang; H-J Kung; C P Evans
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

8.  miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer.

Authors:  Shahana Majid; Altaf A Dar; Sharanjot Saini; Sumit Arora; Varahram Shahryari; Mohd Saif Zaman; Inik Chang; Soichiro Yamamura; Yuichiro Tanaka; Guoren Deng; Rajvir Dahiya
Journal:  Cancer Res       Date:  2012-10-16       Impact factor: 12.701

9.  Gdnf upregulates c-Fos transcription via the Ras/Erk1/2 pathway to promote mouse spermatogonial stem cell proliferation.

Authors:  Zuping He; Jiji Jiang; Maria Kokkinaki; Nady Golestaneh; Marie-Claude Hofmann; Martin Dym
Journal:  Stem Cells       Date:  2007-10-25       Impact factor: 6.277

10.  The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry.

Authors:  Fionnuala Morrish; Nicola Neretti; John M Sedivy; David M Hockenbery
Journal:  Cell Cycle       Date:  2008-02-08       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.